Everything below concerns GHRH analogue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-07. Numbers and descriptions here follow the published literature rather than marketing material.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The internal diameter of these vessels expands exponentially in the first hours and days following an occlusion, as mitotic division of the cell wall narrows the wall's diameter and expands each vessel's lumen.Within four weeks, the functional capacity of the vessels has reached a maximum, accompanied by a 90% reduction in their resistance, though structural remodeling continues by cell proliferation and synthesis of elastin and collagen over a period of up to six months. Schaper summarizes the status-2009 knowledge of coronary collateral transformation in a recent review: "Following an arterial occlusion outward remodeling of pre-existent inter-connecting arterioles occurs by proliferation of vascular smooth muscle and endothelial cells. This is initiated by deformation of the endothelial cells through increased pulsatile fluid shear stress (FSS) caused by the steep pressure gradient between the high pre-occlusive and the very low post-occlusive pressure regions that are interconnected by collateral vessels. Shear stress leads to the activation and expression of all nitric oxide synthetase (NOS) isoforms and nitric oxide production, followed by vascular endothelial growth factor (VEGF) secretion, which induces monocyte chemoattractant protein-1 (MCP-1) synthesis in the endothelium and in the smooth muscle of the media. This leads to attraction and activation of monocytes and T-cells into the adventitial space (peripheral collateral vessels) or attachment of these cells to the endothelium (coronary collaterals).
==== Europe ==== In the Netherlands, diamorphine is a List I drug of the Opium Law. It is available for prescription under tight regulation exclusively to long-term addicts for whom methadone maintenance treatment has failed. It cannot be used to treat severe pain or other illnesses. In the United Kingdom, diamorphine is available by prescription, though it is a restricted Class A drug. According to the 50th edition of the British National Formulary (BNF), diamorphine hydrochloride may be used in the treatment of acute pain, myocardial infarction, acute pulmonary oedema, and chronic pain. The treatment of chronic non-malignant pain must be supervised by a specialist. The BNF notes that all opioid analgesics cause dependence and tolerance but that this is "no deterrent in the control of pain in terminal illness". When used in the palliative care of cancer patients, diamorphine is often injected using a syringe driver. In Switzerland, heroin is produced in injectable or tablet form under the brand name Diaphin by a private company under contract to the Swiss government. Swiss-produced heroin has been imported into Canada with government approval.
==== Quantitative dating ==== A number of spots within an age domain are selected and further dated accurately with the measurement tools by isotopic dating method. The results are then analysed statistically to give an accurate age of each age domain.
Writer George Orwell used cold war, as a general term, in his essay "You and the Atomic Bomb", published 19 October 1945. Contemplating a world living in the shadow of the threat of nuclear warfare, Orwell looked at James Burnham's predictions of a polarized world, writing:
=== Landmine removal === Thiokol has used surplus rocket fuel through an agreement with NASA's Marshall Space Flight Center to produce a flare that can safely destroy landmines. The fuel that is left unused from a launch will become a solid, which cannot be reused but can be used as an ingredient needed to create the Demining Device flare. The Demining Device flare uses a battery-triggered electric match to ignite and neutralize land mines in the field without detonation. The flare uses the solid rocket fuel to burn a hole in a mine's case and burns away the explosive contents so the mine can be disarmed without hazard.
Sources: en.wikipedia.org
==== Herpetology ==== Reptiles need UV‑B for biosynthesis of vitamin D, and other metabolic processes. Specifically cholecalciferol (vitamin D3), which is needed for basic cellular / neural functioning as well as the utilization of calcium for bone and egg production. The UV‑A wavelength is also visible to many reptiles and might play a significant role in their ability survive in the wild as well as in visual communication between individuals. Therefore, in a typical reptile enclosure, a fluorescent UV‑A / UV‑B source (at the proper spectrum strength and coverage for the species), must be available for many captive species to survive. Simple supplementation with cholecalciferol (vitamin D3) will not be enough as there is a complete biosynthetic pathway that is metabolically "leap-frogged" (risks of possible overdoses), the intermediate molecules and metabolites also play important functions in the animals health. Natural sunlight in the right levels is always going to be superior to artificial sources, but this might not be possible for keepers in different parts of the world. It is a known problem that high levels of output of the UV‑A part of the spectrum can both cause cellular and DNA damage to sensitive parts of their bodies – especially the eyes where blindness is the result of improper UV‑A and UV‑B source placement and use (an overdose is called photokeratitis). For many keepers there must also be a provision for an adequate heat source this has resulted in the marketing of heat and light "combination" products.
In 2023, world production of peppermint was 35,547 tonnes, led by Morocco with 78% of the total and Argentina with 20% (table). In 2020, Oregon and Washington produced most of American peppermint, the leaves of which are processed for the essential oil to produce flavourings mainly for chewing gum and toothpaste.
In 1912, Alfred Eric Frank, then working on diabetes mellitus in the department of Oskar Minkowski in Breslau, reported a specific link to the pituitary gland upon observing a case of a man who had survived after shooting himself in the temple. Morris Simmonds drew the same connection in 1913. Thereafter, numerous reports documented cases of diabetes insipidus associated with pituitary lesions, steadily accumulating evidence favouring the hypothesized connection. George Oliver and Edward Albert Schafer were among the first researchers to document its endocrine functions. In the first two decades of the 20th century, however, a number of conflicting reports on the diuretic versus anti-diuretic properties of the pituitary extract caused confusion in the field. A general agreement was reached that some of the results that reported diuresis was due to increased pressure and blood flow to the kidney, while the posterior pituitary extract had an antidiurectic effect. By the 1920s, accumulated findings defined diabetes insipidus as a disorder of the pituitary. The main question now became whether the cause of diabetes insipidus lay in the pituitary gland or the hypothalamus, given their intimate connection. In 1920, Jean Camus and Gustave Roussy summarized a number of years of research, reporting that they had produced polyuria in dogs by puncturing the hypothalamus while leaving the pituitary intact. These results were later replicated by many others.
== The role in human pregnancy == In humans, a certain subtype of cells of the placenta, namely the extravillous trophoblasts, express the enzyme and secrete it into the blood stream of a pregnant woman. During pregnancy, DAO helps maintaining fetal growth and development by regulating histamine levels. DAO levels in the blood circulation increase vastly in pregnant women suggesting a protective mechanism against adverse histamine. Histamine is a potent vasodilator and can cause uterine contractions, which can lead to premature labor. DAO in the placenta breaks down histamine to prevent its accumulation and maintain a healthy pregnancy. Low levels of DAO in the placenta may contribute to preeclampsia, a pregnancy-related disorder characterized by mother's high blood pressure and damage to mother's organs such as the liver and kidneys; the baby may also be affected if the condition is severe or left untreated, but it is not the primary target of the disorder. Lowered diamine oxidase values in maternal blood in early pregnancy might be an indication for trophoblast-related pregnancy disorders like early-onset preeclampsia.
Sources: en.wikipedia.org
=== Laminin EGF-like === Beside different types of globular domains each laminin subunit contains, in its first half, consecutive repeats of about 60 amino acids in length that include eight conserved cysteines. The tertiary structure of this domain is remotely similar in its N-terminus to that of the EGF-like module. It is also known as a 'LE' or 'laminin-type EGF-like' domain. The number of copies of the laminin EGF-like domain in the different forms of laminins is highly variable; from 3 up to 22 copies have been found. In mouse laminin gamma-1 chain, the seventh LE domain has been shown to be the only one that binds with a high affinity to nidogen. The binding-sites are located on the surface within the loops C1-C3 and C5-C6. Long consecutive arrays of laminin EGF-like domains in laminins form rod-like elements of limited flexibility, which determine the spacing in the formation of laminin networks of basement membranes.
mole (mol) A unit (symbol: mol) used to measure the amount of a substance in terms of the absolute number of particles or entities composing the substance. By definition, one mole of any substance contains exactly the Avogadro number (i.e. 6.022×1023) of particles or entities.
The favoured model for the enzyme–substrate interaction is the induced fit model. This model proposes that the initial interaction between enzyme and substrate is relatively weak, but that these weak interactions rapidly induce conformational changes in the enzyme that strengthen binding. These conformational changes also bring catalytic residues in the active site close to the chemical bonds in the substrate that will be altered in the reaction. Conformational changes can be measured using circular dichroism or dual polarisation interferometry. After binding takes place, one or more mechanisms of catalysis lower the energy of the reaction's transition state by providing an alternative chemical pathway for the reaction. Mechanisms of catalysis include catalysis by bond strain; by proximity and orientation; by active-site proton donors or acceptors; covalent catalysis and quantum tunnelling. Enzymes can accelerate hydrogen transfer reactions by quantum tunneling, a phenomenon where particles such protons or electrons pass through an energy barrier rather than over it, due to their wave-like nature. Enzyme kinetics cannot prove which modes of catalysis are used by an enzyme. However, some kinetic data can suggest possibilities to be examined by other techniques. For example, a ping–pong mechanism with burst-phase pre-steady-state kinetics would suggest covalent catalysis might be important in this enzyme's mechanism.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.